2022
Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch–Anal Anastomosis in Pediatric Ulcerative Colitis
Runde J, Erondu A, Akiyama S, Traboulsi C, Rai V, Glick L, Yi Y, Ollech J, Cohen R, Skowron K, Hurst R, Umanskiy K, Shogan B, Hyman N, Rubin M, Dalal S, Sakuraba A, Pekow J, Chang E, Rubin D. Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch–Anal Anastomosis in Pediatric Ulcerative Colitis. Inflammatory Bowel Diseases 2022, 28: 1386-1394. PMID: 35040964, PMCID: PMC9434476, DOI: 10.1093/ibd/izab319.Peer-Reviewed Original ResearchConceptsIleal pouch-anal anastomosisPediatric ulcerative colitisPouch-anal anastomosisUlcerative colitisYears of agePouch survivalAdult patientsRetrospective single-center studyIleoanal pouch anastomosisAnti-TNF therapySingle-center studyKaplan-Meier curvesLog-rank testKaplan-Meier estimatesPediatric control subjectsElectronic medical recordsChi-square testPouch anastomosisPouch failureTotal proctocolectomyPediatric patientsSurgical outcomesControl subjectsMedical recordsRapid progression
2019
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid‐refractory ulcerative colitis
Ollech J, Dwadasi S, Rai V, Peleg N, Normatov I, Israel A, Sossenheimer P, Christensen B, Pekow J, Dalal S, Sakuraba A, Cohen R, Rubin D. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid‐refractory ulcerative colitis. Alimentary Pharmacology & Therapeutics 2019, 51: 637-643. PMID: 31875986, DOI: 10.1111/apt.15616.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, Monoclonal, HumanizedCalcineurin InhibitorsColitis, UlcerativeDrug Administration ScheduleDrug ResistanceFemaleFollow-Up StudiesHumansInduction ChemotherapyMaintenance ChemotherapyMaleProgression-Free SurvivalRetrospective StudiesSeverity of Illness IndexSteroidsTreatment OutcomeYoung AdultConceptsSevere steroid-refractory ulcerative colitisSteroid-refractory ulcerative colitisCalcineurin inhibitorsInduction therapyMaintenance therapyUlcerative colitisVedolizumab initiationMedian timeWeek 14Colectomy-free survival ratesSevere steroid-refractory colitisColectomy-free survivalSteroid-refractory colitisVedolizumab maintenance therapyInduction of remissionSerious adverse eventsSevere ulcerative colitisRetrospective observational studyEnd of inductionBiochemical remissionVedolizumab discontinuationClinical remissionPrimary endpointSecondary endpointsAdult patients